NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Marker Therapeutics, Inc. MRKR
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$3.5M
▼ 46.2% vs FY2024
EPS · FY25
$-0.79
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-68.8%
Net margin · FY25
-343.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 3.5M
Revenue, FY2025 · full 19-year series below
Revenue
Net income
The company lost 343 cents on every revenue dollar this year.
Per share
USD -0.79
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-68.8%
Return on equity, FY2025
ROE
Operating margin-363.5%
Net margin-343.0%
Return on assets-59.2%
Each USD of equity lost 69 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+50.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+0.3%
+50.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 19.1M
total assets, end of FY2025
Total assetsUSD 19.1M
EquityUSD 16.8M
CashUSD 16.1M
Current ratio8.39×
Equity funds 88% of total assets.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
·
−0.0
−0.0
·
·
·
EBITDA $B
·
·
·
−0.0
−0.0
−0.0
−0.0
·
·
·
·
·
·
·
·
·
·
·
·
Income tax $B
−0.0
0.0
0.0
·
·
·
·
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.79
−1.19
−0.94
−3.58
−5.47
−0.61
−0.47
−7.75
−1.16
−0.72
−9.30
−2.00
−4.87
−9.42
−0.04
−0.09
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−68.8
−65.8
−49.0
−94.1
−117.4
−80.4
−41.4
−469.7
−223.2
·
·
·
·
·
·
·
·
·
·
Shares out B
0.02
0.01
0.01
0.01
0.01
0.05
0.05
0.05
0.01
0.01
0.01
0.02
0.00
0.00
0.05
0.04
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
39 of 41
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 2 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed